1026MO A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors
R-H. Xu(Sun Yat-sen University), Shujie Wang(Jiangsu Hengrui Medicine (China)), Zhihong Niu, Hong Pan(Beijing Institute of Technology), Mingu Kang(Seoul National University), Shanzhi Gu(Central South University), Juan Zhou(Jiangnan University), Haixia Zhao(Southwest University of Science and Technology), Hui Ren(Union Hospital), Yi Wang(Anhui University of Traditional Chinese Medicine), Ying Zhang(Sun Yat-sen University), Jian Zhang(Zhujiang Hospital), Pan Liu(Fuzhou University), Zhonghan Zhang(Jiangsu Hengrui Medicine (China)), Dandan Ma(Zhengzhou University), Xiaohui Yin(Hunan Cancer Hospital), Wenjun Wei(Ministry of Education of the People's Republic of China), Yicheng Ni(Shanxi Province Hospital of Traditional Chinese Medicine)
Cited by 1
Related Papers
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
NF-κB in biology and targeted therapy: new insights and translational implications
|Signal Transduction and Targeted Therapy|2024|1.6k
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
A Layered P2‐ and O3‐Type Composite as a High‐Energy Cathode for Rechargeable Sodium‐Ion Batteries
|Angewandte Chemie International Edition|2015|427